A 65 F WITH STATUS EPILEPTICUS AND K/C/O EPILEPSY SINCE 21 YEARS

 

  

 This is an online e log book to discuss our patient de-identified health data shared after taking his / her / guardians signed informed consent. Here we discuss our individual patients problems through series of inputs from available global online community of experts with an aim to solve those patients clinical problem with collective current best evident based input.

This E blog also reflects my patient centered online learning portfolio and your valuable inputs on the comment box is welcome.

I have been given this case to solve in an attempt to understand the topic of " patient clinical data analysis" to develop my competency in reading and comprehending clinical data including history, clinical findings, investigations and come up with diagnosis and treatment plan.

A 65 year old female came to casuality with chief complaints involuntary movements of B/L upper limbs and lower limbs.

HOPI:-

 A 65 years old female came to casualty with 

C/C of headache since 4 hours

Involuntary movements in right upper and lower limbs since 3 hours

Hopi:

Patient was apparently asymptomatic 4 hours back then she developed headache in frontal region, sudden in onset, took seizure medication levipil 500 mg after an hour or so Involuntary movements in right upper and lower limbs associated with fall , 2 episode every 5 mins, each episode lasted for 2-3 mins. 

Associated with uprolling of eyeballs, frothing from the mouth, involuntary defection and is unresponsive since 3 hours

No H/O fever or vomitings

PAST HISTORY:- 

Known case of seizure disorder since 21 years, taking tab. Levipil 500 mg.

H/O head surgery for meningioma 21 years back.

N/k/c/o DM, HTN, Asthma, CAD, CVA, TB

Active seizure episode in casuality:

GENERAL PHYSICAL EXAMINATION 

Pt is on ventilator 

pallor, icterus, cyanosis, clubbing, lymphadenopathy, edema were absent.

Bp: 120/70 mmHg

PR: 90 bpm

SpO2: 100% on FiO2 100

Crash intubation was done 

SYSTEMIC EXAMINATION:

CVS:

Inspection:

There are no chest wall abnormalities 

The position of the trachea is central. 

Apical impulse is not observed. 

There are no other visible pulsations, dilated and engorged veins, surgical scars or sinuses. 

Palpation:

Apex beat was localised in the 5th intercostal space 2cm lateral to the mid clavicular line 

Position of trachea was central 

There we no parasternal heave , thrills, tender points. 

Auscultation: 

S1 and S2 were heard 

There were no added sounds / murmurs. 

Respiratory system:

Bilateral air entry is present 

Normal vesicular breath sounds are heard. 

Per Abdomen:

Shape is scaphoid

Abdomen is soft and non tender with no signs of organomegaly

Bowel sounds are heard

CNS: 

GCS :- E2V1M4

HIGHER MENTAL FUNCTIONS- couldn't be elicited 

Memory :- couldn't be elicited 

CRANIAL NERVES : couldnt be assessed 

Sensory examination:- 

MOTOR EXAMINATION

Normal tone in upper and lower limb

Power:- couldn't be assessed 

Gait: couldnt asses the patient was ventilated

REFLEXES

Normal, brisk reflexes elicited- biceps, triceps, knee and ankle reflexes elicited

CEREBELLAR FUNCTION :- couldn't be elicited 

Provisional diagnosis: STATUS EPILEPTICUS 

FOCAL SEIZURES WITH SECONDARY GENERALISATION WITH TYPE 2 RESPIRATORY FAILURE SECONDARY TO POST ICTAL CONFUSION 

MRI:-  

EEG:-

Investigations:-

Chest X Ray

8/5/23

9/5/23

                        X ray pelvis AP view

                            Lab Investigations

Hemogram:-

8/5/23

HEMOGLOBIN- 13.9

PCV  - 42.1

TLC  -10 200

RBC  -4.83

PLATELET COUNT  - 2.44LAKH

9/5/23

HEMOGLOBIN   - 13.9

PCV   -37.6

TLC   -9500

RBC   -4.36

PLATELET COUNT  -2.23LAKH

ABG:-

8/5/23        8:40 am      5:10 pm( pt was intubated)

   pH       -> 7.07              7.4

   pCO²   ->  95.3             33.6

   pO²     ->  114              282

   HCO³‐ ->  26.4             20.4

9/5/23        7:40 am      6:40 pm

   pH       ->  7.43              7.48

   pCO²   ->  30.1             28.4

   pO²     ->  124              93.2

   HCO³‐ ->  19.7             21.3

10/5/23

   pH       -> 7.46            

   pCO²   ->  31.5           

   pO²     ->  74.1           

   HCO³‐ ->  22.4

 RFT         8/5/23    9/5/23    10/5/23    11/5/23

B. Urea     31           l32

Sr.Creat    0.8          0.9

Na+           142        140         137           143

K+              4.2         4.0          3.6            3.6

Cl-              104        104         103           104

LFT

T. Bil          1.07

D. Bil          0.22

SGOT         37

SGPT         19

Alk. Phos  179

            

COURSE IN THE HOSPITAL:-

A 65 YEAR OLD FEMALE PRESENTED WITH ABOVE MENTIONED COMPLAINTS AND WAS

EVALUATED CUNICALLY AND WITH APPROPRIATE INVESTIGATIONS, PATIENT WAS

DIAGNOSED WITH STATUS EPILEPTICUS SECONDARY TO LEFT PARIETAL

ENCEPHALOMALACIA FOCAL SEIZURES SECONDARY TO GENERALIZATION

PATIENT PRESENTED TO CASUALITY WITH STATUS EPILEPTICUS AND WAS MANAGED

CONSERVATIVELY INIO REFRACTORY SEIZURES AND TYPE 2 RESPIRATORY FAILURE

EMERGENCY INTUBATION WAS DONE

MRI WAS DONE AND ENCEPHALOMALACIA IN THE LEFT PARIETAL REGION WAS NOTICED

PATIENT WAS ON MIDAZOLAM INFUSION FOR 1 AND HALF DAY AND INFUSION WAS

TAPERED AND MECHANICAL VENTILALƏN SETTINGS WERE CHANGED FROM 

ACMV--->CPAP---> WAS EXTUBATED THE FOLLOWING DAY ---> NO FURTHER SEIZURE ACTIVITY WAS NOTICED PATIENT WAS ON DUALANTI EPILEPTIC INJ. LEVITARECITAM AND INJ. SODIUM VALPROATE, THEN CHANGED TO DUAL ANTIEPILEPTIC THERAPY ON TAB. LEVITARECITAM AND TAB. SODIUM VALPROATE

EEG WAS DONE WHICH SHOWED NO ABNORMALITIES AND NEUROLOGIST OPINION WAS TAKEN AND ADVICED TO CONTINUE

SAME TREATMENT

GENERAL SURGERY OPINION WAS TAKEN I/O GRADE 1 BED SORE AND ADVICED

REGULAR DRESSING WITH NEOSPORIN

PATIENT HAS RECOVERED SYMPTOMATICALLY AND DISCHARGED IN STABLE CONDITION

FINAL DIAGNOSIS:-

1)STATUS EPILEPTICUS(RESOLVED) SECONDARY TO LEFT PARIETAL ENCEPHALOMALACIA

FOCAL SEIZURES  With 2⁰ GENERALIZATION

2)TYPE 2 RESPIRATORY FAILURE(RESOLVED) SECONDARY TO POST ICTAL CONFUSION

3)DENOVO HBSAG(POSITIVE) WITHSP POST EXTUBATION ON 10/5/23(9:30AM) KNOWN

CASE OF SEIZURES SINCE 16YEAR

4)HISTORY OF SURGERY FOR MENINGIOMA IN 2007

Treatment: 

Inj.DICLOFENAC IM SOS

Tab.SODIUM VALPROATE 200MG PO/BD

Tab.LEVIPIL 500MG PO/BD

Tab. PAN 40 mg PO/OD BBF

NEOSPORIN DRESSINGS FOR BED SORE.

Discussion:-

[08/05, 21:13] Rakesh Biswas Sir GM HOD: ABG repeated? 

Sedation rate? Share the complete details of ventilation settings and current pharmacological dose and drip rate

[10/05, 21:33] Ajay Sir Pg GM: https://pubmed.ncbi.nlm.nih.gov/20581136/

[10/05, 21:36] Rakesh Biswas Sir GM HOD: So with this information what does your patient fit into?

[10/05, 21:36] Ajay Sir Pg GM: https://go.gale.com/ps/i.do?p=AONE&u=googlescholar&id=GALE|A128075131&v=2.1&it=r&sid=AONE&asid=7d1af1d7

[10/05, 21:37] Ajay Sir Pg GM: Source

[10/05, 21:40] Ajay Sir Pg GM: The patient fits mostly into true seizures sir 

The patient doesn't have any intention to do pseudoseizures as per the history provided by the attenders and patient , 

There is rigidity f/b jerking, 

There is involuntary defecation and micturition

[10/05, 22:50] Rakesh Biswas Sir GM HOD: Any review of literature around respiratory and metabolic acidosis in seizures similar to what our patient had?

[11/05, 08:35] Dr. Navya Ma’am PG GM: https://www.ncbi.nlm.nih.gov/books/NBK441871/

Treatment of PNES may be difficult, but it is clear that anti-epileptic drugs (AEDs) are of no benefit. In addition to unnecessary costs and the potential side effects of AEDs for these patients, life-threatening side effects such as respiratory depression may occur if psychogenic nonepileptic status epilepticus is treated with large dosages of benzodiazepines.

[11/05, 09:19] Ajay Sir Pg GM: https://linkinghub.elsevier.com/retrieve/pii/S0007-0912(17)47615-X

[11/05, 09:25] Ajay Sir Pg GM: https://pubmed.ncbi.nlm.nih.gov/1191463/

[11/05, 11:57] Rakesh Biswas Sir GM HOD: Share the images of encephalomalacia from this patient's MRI as well as the previous patient with migraine and visual loss asap @⁨Dr. Navya Ma’am PG GM⁩

[14/05, 08:54] Rakesh Biswas Sir GM HOD: 👆MRI images of encephalomalacia ? @⁨Dr. Deepika Ch GM PG Ma'am⁩

[15/05, 23:59] Dr. Deepika Ch GM PG Ma'am: Age, number of lesion sites, size of encephalomalacia, and seizure frequency were independent risk factors for the prognosis of patients with REAE (OR > 1, P < 0.05). Surgical treatment was an independent protective factor associated with the prognosis of patients with REAE

variety of causes can lead to liquefaction and necrosis of brain tissue and the formation of encephalomalacia [9]. These causes include trauma, cerebrovascular disease, and intracranial infection [10]. The pathological manifestations of brain soft focus ranged from early neuronal necrosis to neuronal disappearance and then to glial cell proliferation. There are no nerve cells in the brain softening focus, which does not cause epileptic discharge. The real pathological site of epileptic discharge is the peripheral nerve tissue [11]. The traction of fibrous scar tissue in the brain can embed the remaining normal neurons cause abnormal discharge and disrupt the function of intertwined proliferative cells. It affects the electrical activity of normal neurons, resulting in seizures. A study suggested that glial cells can lead to epileptic seizures through mechanisms such as increasing the excitability of normal neurons, neuronal cluster discharge, and failure to inhibit the excitability of neurons

[15/05, 23:59] Dr. Deepika Ch GM PG Ma'am: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9273423/

[16/05, 00:00] Dr. Deepika Ch GM PG Ma'am: The predictive efficacy of encephalomalacia size on the prognosis of patients with refractory epilepsy secondary to encephalomalacia. AUC: area under the curve; CI: confidence interval.

[16/05, 00:00] Dr. Deepika Ch GM PG Ma'am: Efficacy of seizure frequency in predicting prognosis in patients with refractory epilepsy secondary to encephalomalacia. AUC: area un

[16/05, 00:02] Dr. Deepika Ch GM PG Ma'am: refractory epilepsy associated with encephalomalacia (REAE).

[16/05, 06:47] Rakesh Biswas Sir GM HOD: For the AJND article :

Can encephalomalacia be a form of neurodegeneration?

[16/05, 10:39] Dr. Deepika Ch GM PG Ma'am: Encephalomalacia also known as cerebromalacia, is the softening of brain tissue. It can be caused either by vascular insufficiency, and thus insufficient blood flow to the brain, or by degeneration. Encephalomalacia can be the formation of necrosis, or dead tissue, in a portion of the brain due to a partial complete blockage of blood flow to the area, which in turn can be caused by a natural condition or by infection or trauma (TBI). The term encephalomalacia is also used at times to refer more generally to degenerative conditions affecting the brain. If the condition affects the white matter of the brain, it is called leukoencephalomalacia. If it affects the gray matter, it is known as polioencephalomalacia.

[16/05, 10:40] Dr. Deepika Ch GM PG Ma'am: https://www.passenpowell.com/encephalomalacia-brain-injury-children-adults/

[17/05, 07:18] Rakesh Biswas Sir GM HOD: What about microscopic description of the pathology in encephalomalacia?

Also focus on it's association with vascular neurodegeneration 

Also share the MR images of the 35F with CRVO and Vascular migraine and encephalomalacia

[20/05, 13:14] Dr. Deepika Ch GM PG Ma'am: CAA has now been linked with brain atrophy in regions remote from those directly affected by intracerebral hematomas, and with risk for progressive cognitive decline in the absence of new hemorrhagic strokes. Therefore, CAA is associated with features – brain atrophy and progressive cognitive decline – that are typically considered hallmarks of neurodegenerative disease. Although CAA is usually accompanied by some degree of Alzheimer's disease pathology, the profiles of cortical thinning and cognitive impairment do not fully overlap with those seen in Alzheimer's disease, suggesting that there are CAA-specific pathways of neurodegeneration. CAA-related brain ischemia may be an important mechanism that leads to brain injury, cortical disconnection, and cognitive impairment

The terms ‘neurodegeneration’ and ‘neurodegenerative’ are widely used but without a formal definition in the peer-reviewed literature. The terms are frequently used to refer to a group of neurological conditions marked by death of neurons and supporting cells in the neurovascular unit, with accompanying progressive loss of cognitive and motor functions.

Stroke and other forms of monophasic acute brain injury (e.g., because of trauma) are not typically considered to be neurodegenerative disorders. Therefore, CAA is most commonly conceptualized as a cerebrovascular disease associated with risk of lobar ICH, and not as a cause of neurodegeneration. However, accruing evidence suggests that CAA is not so easy to pigeonhole as either a cause of stroke or neurodegeneration, but instead is an important cause of both of these neurological syndromes. To make my case that CAA should be considered a neurodegenerative disease, I focus on associations between CAA and two cardinal features of neurodegenerative diseases: cognitive decline and brain atrophy

Both are a consequence of cleavage of the amyloid precursor protein to form pathogenic Aβ which aggregates into β-amyloid. In the case of AD pathology, the β-amyloid aggregates in the brain parenchyma in the form of neuritic plaques. In the case of CAA, the β-amyloid aggregates in the walls of small arteries and arterioles. Most patients with CAA also have some degree of neuritic plaques, and most patients with AD have some degree of CAA

pattern of cortical thinning in CAA (Fotiadis et al. 2016) overlaps with AD (Dickerson et al. 2009) in some regions (supramarginal gyrus, superior frontal gyrus, and inferior temporal gyrus), but other regions exhibit more thinning in CAA than AD (occipital cortex and medial frontal cortex) or in AD than CAA (precuneus, angular gyrus, and anterior temporal cortex) (Fig. 2). Overall, there are clear differences between the CAA and AD patterns of cortical thinning.

These differences in cognitive profile and regional cortical thinning suggest that neurodegeneration in CAA cannot be solely attributed to the effects of concomitant AD pathology.